Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

01.03.19	Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication (GlobeNewswire)
27.02.19	Biotech Stocks Facing FDA Decision In March (RTTNews)
25.02.19	Amgen: Delaware Jury Upholds Validity Of Two Patents Related To PCSK9 Antibodies (RTTNews)
25.02.19	Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps (GlobeNewswire)
12.02.19	Sanofi appoints Ameet Nathwani Chief Digital Officer (GlobeNewswire)
11.02.19	Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts (RTTNews)
07.02.19	Sanofi Q4 Profit Surges, Sees Earnings Growth In FY19 (RTTNews)
07.02.19	Sanofi Q4 Profit Doubles; Sees Growth In FY19 Business EPS (RTTNews)
06.02.19	Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director (GlobeNewswire)
06.02.19	Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) (GlobeNewswire)
05.02.19	AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility (RTTNews)
05.02.19	Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma (GlobeNewswire)
04.02.19	Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease (GlobeNewswire)
25.01.19	AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis (RTTNews)
18.01.19	FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz (RTTNews)
18.01.19	FDA Advisory Panel Splits Vote On Sanofi-Lexicon Diabetes Drug (RTTNews)
18.01.19	Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes (GlobeNewswire)
07.01.19	Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs (GlobeNewswire)
03.01.19	MYOK Falls On Sanofi Deal Update, YMAB On Track, EQ Braces For Busy Year Ahead (RTTNews)
27.12.18	FDA Approves Sanofi And Merck's Pediatric Hexavalent Combination Vaccine Vaxelis (RTTNews)
27.12.18	Dr. Reddy's Labs Unveils Renvela Generic Sevelamer Carbonate In U.S (RTTNews)
26.12.18	Opiant Licenses Novel CB-1 Receptor Antagonist For Treatment Of ACO From Sanofi (RTTNews)
24.12.18	Biotech Stocks Facing FDA Decision In January 2019 (RTTNews)
19.12.18	Sanofi-Aventis Reports EU Approval Of Dengue Vaccine - Quick Facts (RTTNews)
19.12.18	Dengvaxia® vaccine approved for prevention of dengue in Europe (GlobeNewswire)
18.12.18	Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq (GlobeNewswire)
13.12.18	Mylan : Sanofi' Formulation Patents On Lantus Invalidated By U.S. Patent Office (RTTNews)
30.11.18	FDA Warns About Serious Side Effects Of Multiple Sclerosis Drug (RTTNews)
16.11.18	Sanofi-Aventis: CHMP Adopts Positive Scientific Opinion Of Fexinidazole (RTTNews)
16.11.18	Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness (GlobeNewswire)
13.11.18	AstraZeneca To Divest U.S. Synagis Rights To Sobi (RTTNews)
11.11.18	Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause (GlobeNewswire)
07.11.18	New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial (GlobeNewswire)
06.11.18	Regeneron : FDA Grants Priority Review For Dupixent (RTTNews)
06.11.18	FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (GlobeNewswire)
01.11.18	Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases (GlobeNewswire)
31.10.18	Sanofi Q3 Profit Up 45.7% - Quick Facts (RTTNews)
22.10.18	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch (RTTNews)
19.10.18	Sanofi: FDA approves asthma indication for Dupixent® (dupilumab) (GlobeNewswire)
19.10.18	Sanofi Gets Positive CHMP Opinion For Dengue Vaccine - Quick Facts (RTTNews)
19.10.18	Sanofi receives positive CHMP opinion for dengue vaccine (GlobeNewswire)
16.10.18	Regeneron : Dupixent Shows Positive Results In Two Phase 3 Trials On CRSwNP (RTTNews)
16.10.18	Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps (GlobeNewswire)
28.09.18	Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma (GlobeNewswire)
28.09.18	Sanofi: Availability of the Pre-quarterly Results Communication (GlobeNewswire)
15.09.18	Sanofi Reports Positive Results From Phase 3 Dupixent Study (RTTNews)
15.09.18	Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab) (GlobeNewswire)
13.09.18	Sanofi To Change Organizational Structure Of Two Global Business Units (RTTNews)
13.09.18	Sanofi to refocus two global business units (GlobeNewswire)
13.09.18	ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

20:03		Freundlicher Handel: Dow Jones am Nachmittag stärker
20:03		Handel in New York: So performt der NASDAQ 100 am Montagnachmittag
18:01		Börse New York in Grün: So bewegt sich der Dow Jones mittags
18:01		Optimismus in New York: NASDAQ 100 zeigt sich am Mittag fester
18:01		Pluszeichen in New York: So bewegt sich der S&P 500 am Montagmittag
17:58		Schwacher Handel in Zürich: SPI letztendlich leichter
17:58		Montagshandel in London: FTSE 100 bewegt sich zum Handelsende im Plus
17:58		Aufschläge in Frankfurt: TecDAX zum Handelsende auf grünem Terrain

20:03

Freundlicher Handel: Dow Jones am Nachmittag stärker

20:03

Handel in New York: So performt der NASDAQ 100 am Montagnachmittag

18:01

Börse New York in Grün: So bewegt sich der Dow Jones mittags

18:01

Optimismus in New York: NASDAQ 100 zeigt sich am Mittag fester

18:01

Pluszeichen in New York: So bewegt sich der S&P 500 am Montagmittag

17:58

Schwacher Handel in Zürich: SPI letztendlich leichter

17:58

Montagshandel in London: FTSE 100 bewegt sich zum Handelsende im Plus

17:58

Aufschläge in Frankfurt: TecDAX zum Handelsende auf grünem Terrain

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V

Nachrichten zu Sanofi S.A.

Aktien Top/Flop

Sanofi Peer Group Nachrichten

Meistgelesene Nachrichten